Xofigo Treatment: How It Works, Results and What to Expect

Xofigo treatment uses radium-223, a targeted radioactive medicine, to treat certain people with castration-resistant prostate cancer that has spread to bone. It is given as a series of outpatient injections and is designed to target bone metastases while limiting radiation exposure to surrounding tissues.

Overview: what is Xofigo treatment?

Xofigo treatment is a form of targeted radionuclide therapy containing radium-223 dichloride. It is used for some adults with metastatic castration-resistant prostate cancer: prostate cancer that continues to grow despite treatment to lower testosterone and has spread to the bones. Xofigo is intended for people who have symptomatic bone metastases and no known metastases in organs such as the liver or lungs.

After it is injected into a vein, radium-223 behaves in a similar way to calcium and collects in areas where bone is actively remodelling. Bone metastases often create this increased activity. The medicine then releases alpha particles, a high-energy form of radiation that travels only a very short distance, helping to damage cancer cells in and near the affected bone.

Xofigo is not chemotherapy, external-beam radiotherapy or hormone therapy. It may be one part of an individual treatment plan developed by medical oncology, urology, radiation oncology, nuclear medicine and supportive-care teams. The aim is to manage bone-predominant metastatic disease, reduce the risk of serious bone-related problems and help people live longer with the condition.

What kind of cancer does Xofigo treat?

Xofigo is approved for a specific clinical setting: castration-resistant prostate cancer that has spread to bones, causes symptoms and has no known visceral metastases. Symptoms may include bone pain, although the treating team considers the full clinical picture rather than pain alone. It is not a general treatment for every type of prostate cancer or every cancer that has reached bone.

Prostate cancer cells can spread through the bloodstream and settle in bones, commonly the spine, pelvis, ribs or hips. These deposits can weaken bone and may cause pain, fractures or pressure on the spinal cord. A cancer specialist confirms where the cancer has spread using appropriate imaging, blood tests and the person’s treatment history.

Xofigo does not treat cancer deposits outside the skeleton effectively because its action is concentrated in areas of bone turnover. People with lymph-node disease may still be considered in selected circumstances, but known organ metastases generally require other systemic treatment approaches. Decisions should be individualized after careful staging and review.

How Xofigo works and how effective it is

Radium-223 is known as an alpha-emitting radiopharmaceutical. When it reaches bone metastases, its alpha radiation causes breaks in cancer-cell DNA. Because alpha particles travel only a very short distance, their effects are focused near the sites where the medicine accumulates. This differs from beta-emitting bone-targeting radiopharmaceuticals, which have a longer radiation path.

How effective is Xofigo?

In appropriately selected people with symptomatic bone-metastatic castration-resistant prostate cancer, clinical research has shown that radium-223 can improve overall survival and delay symptomatic skeletal events, such as the need for radiation to relieve bone symptoms, spinal cord compression or certain fractures. It may also improve bone pain for some people, although pain control can vary and often requires additional supportive treatment.

The response is assessed over time using symptoms, physical examination, blood counts, alkaline phosphatase and imaging when needed. Prostate-specific antigen, or PSA, may not fall during Xofigo treatment and is not the only measure of benefit. A rise in PSA alone does not necessarily mean the medicine is failing; the oncology team interprets all results together.

Xofigo does not eliminate metastatic prostate cancer and cannot be expected to work equally well for everyone. Treatment benefit depends on disease extent, bone marrow reserve, previous and current therapies, general health and whether the cancer remains confined mainly to bone.

Who may be a candidate for Xofigo treatment?

Before recommending Xofigo, the oncology team checks that the diagnosis and pattern of spread match the treatment indication. A candidate usually has castration-resistant prostate cancer, bone metastases that are causing symptoms, and no known metastases in internal organs. Ongoing androgen-deprivation therapy is commonly continued to maintain low testosterone levels.

Blood tests are essential because bone marrow produces red cells, white cells and platelets. The team checks whether blood counts are adequate before starting treatment and before every subsequent injection. Significant anemia, low platelets or low neutrophil levels may mean treatment needs to be delayed, adjusted or avoided.

Medication review is also important. Xofigo should not be combined with abiraterone acetate plus prednisone or prednisolone because this combination has been associated with a higher risk of fractures and death. Clinicians also consider fracture prevention, including assessment of bone health and whether a bone-protecting medicine is appropriate.

Pregnancy prevention should be discussed. Although Xofigo is used in prostate cancer, radiation can potentially affect an unborn child. Men receiving treatment should follow their care team’s advice about contraception during treatment and for the recommended period afterward.

Xofigo procedure: step by step and recovery timeline

Xofigo is normally delivered in a nuclear medicine or oncology setting as an outpatient procedure. A standard course consists of six intravenous injections, usually given about four weeks apart. The exact schedule may change if blood results, side effects or the person’s health require a pause or reassessment.

Before each appointment, the care team reviews symptoms, current medicines and laboratory results. Once it is safe to proceed, a trained clinician places a small intravenous line and injects the prescribed amount of radium-223 slowly into the vein. The injection itself is generally brief, and the line is flushed afterward.

Most people can return home the same day. There is no prolonged recovery period after the injection, but tiredness or mild digestive symptoms can occur over the following days. The team provides practical radiation-safety instructions, which may include careful handwashing and toilet hygiene because small amounts of radioactivity leave the body mainly through stool.

Follow-up continues throughout the six-month treatment course. Blood counts are checked before every dose and again after treatment if needed. Patients should keep all scheduled tests, report new symptoms promptly and avoid making changes to cancer medicines without guidance from their prescribing clinician.

Benefits, risks and side effects

The potential benefits of Xofigo include a survival advantage in its approved setting and a delay in symptomatic skeletal events. For some people, treatment may help reduce bone-related symptoms or reduce the need for certain bone-directed interventions. It can be an important option when disease is concentrated in the skeleton and the person remains well enough for repeated treatment visits.

The main safety concern is bone marrow suppression. Xofigo can lower red blood cells, white blood cells and platelets, potentially causing anemia, infection risk or unusual bleeding and bruising. This is why routine blood monitoring is not optional. People who already have substantially reduced marrow function may face higher risks.

Other possible side effects include nausea, diarrhea, vomiting, swelling in the legs and reduced appetite. Less commonly, dehydration may develop if vomiting or diarrhea is persistent. Fractures can occur in people with prostate cancer that has spread to bone, particularly when bone health is already compromised; clinicians may recommend strategies to lower this risk.

Severe or continuing side effects should always be discussed with the treatment team. A clinician can determine whether symptoms are related to Xofigo, the cancer itself, another treatment or an unrelated health problem, and can arrange supportive care or alter the treatment plan when necessary.

What is the most successful prostate cancer treatment?

There is no single “most successful” prostate cancer treatment for every person. The best treatment depends on whether the cancer is localized, recurrent or metastatic; how quickly it is growing; the person’s age, overall health and preferences; and the cancer’s molecular features. Early-stage prostate cancer may be managed with active surveillance, surgery or radiation, while advanced disease usually requires systemic treatments.

For metastatic prostate cancer, treatment may include androgen-deprivation therapy, androgen-receptor pathway inhibitors, chemotherapy, targeted medicines, immunotherapy for selected molecular profiles, radiopharmaceuticals and symptom-directed treatments. Xofigo is one option for a narrow group of people with symptomatic bone metastases and no known organ metastases.

A multidisciplinary discussion helps identify the sequence of therapies most likely to suit an individual situation. A treatment that is highly effective for one person may not be appropriate for another, so decisions should be made with an experienced cancer team after reviewing imaging, pathology, laboratory findings and prior therapies.

How much does Xofigo cost?

The cost of Xofigo treatment varies substantially by country, hospital, insurance coverage, treatment setting, required tests and supportive medicines. A reliable estimate should include not only the injections themselves but also consultations, imaging, laboratory monitoring and management of any side effects.

Patients are encouraged to ask the hospital’s financial counseling or international patient services team for an individualized written estimate. Insurers or national health systems may have specific eligibility, authorization and reimbursement requirements. The treating team can also explain whether alternative treatments may be clinically appropriate.

When to seek medical care

People receiving Xofigo should contact their oncology team promptly for fever, chills, unusual bruising or bleeding, severe weakness, worsening shortness of breath, persistent vomiting or diarrhea, or signs of dehydration. New severe back pain, leg weakness, numbness, difficulty walking, or new trouble controlling bladder or bowel function requires urgent medical assessment because it may indicate spinal cord compression.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat prostate cancer for international patients. Care planning should always be guided by the treating oncology team and tailored to the individual’s disease and health needs.

Frequently asked questions

Is Xofigo chemotherapy?

No. Xofigo is a radiopharmaceutical containing radium-223, not a chemotherapy drug. It is injected into a vein and targets areas of increased bone activity around prostate cancer bone metastases.

How long does Xofigo treatment take?

A typical course includes six injections given about four weeks apart, lasting roughly six months. Each injection visit is usually outpatient, but blood tests and clinical review are needed before each dose.

Can PSA increase during Xofigo treatment?

Yes. PSA may stay the same or rise during Xofigo treatment, even when the treatment is providing benefit in the bones. Doctors use symptoms, blood counts, alkaline phosphatase, scans and other clinical information rather than PSA alone to assess response.

What precautions are needed after a Xofigo injection?

The treatment team provides specific instructions, often focused on careful bathroom hygiene and handwashing because small amounts of radioactivity are passed mainly in stool. Patients should follow their center’s guidance closely and ask about any household, caregiving or travel concerns.

Can Xofigo be given with other prostate cancer treatments?

Some prostate cancer treatments, including ongoing androgen-deprivation therapy, may continue during Xofigo treatment. However, Xofigo should not be used together with abiraterone acetate plus prednisone or prednisolone, and all medicines should be reviewed by the oncology team.

Does Xofigo cure prostate cancer?

Xofigo does not cure metastatic castration-resistant prostate cancer. In eligible patients, it can help extend survival and delay certain bone-related complications, while supportive care and other cancer treatments may also be used as appropriate.

References

• U.S. Food and Drug Administration
• European Medicines Agency
• National Cancer Institute
• European Association of Urology
• American Cancer Society

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.